Fairfield Financial Advisors LTD Makes New Investment in Danaher Co. (NYSE:DHR)

Fairfield Financial Advisors LTD acquired a new position in shares of Danaher Co. (NYSE:DHR) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 5,538 shares of the conglomerate’s stock, valued at approximately $1,384,000.

Other large investors have also modified their holdings of the company. Patrick M Sweeney & Associates Inc. increased its position in shares of Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after purchasing an additional 40 shares during the period. Trust Co of Kansas raised its position in Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after acquiring an additional 40 shares in the last quarter. Abacus Planning Group Inc. boosted its position in shares of Danaher by 0.7% during the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares in the last quarter. ST Germain D J Co. Inc. grew its stake in shares of Danaher by 1.4% in the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after purchasing an additional 41 shares during the last quarter. Finally, Premier Path Wealth Partners LLC raised its holdings in shares of Danaher by 1.8% in the 2nd quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock worth $586,000 after purchasing an additional 42 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Trading Up 0.6 %

NYSE:DHR opened at $274.25 on Monday. The company’s 50 day moving average is $264.55 and its 200-day moving average is $256.51. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The firm has a market cap of $198.07 billion, a price-to-earnings ratio of 46.48, a P/E/G ratio of 4.48 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the firm posted $2.05 EPS. The business’s quarterly revenue was down 2.9% on a year-over-year basis. Equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s dividend payout ratio is presently 18.31%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DHR. Barclays lifted their price target on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. TD Cowen lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Leerink Partners upped their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Finally, Stifel Nicolaus lifted their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $278.94.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 in the last 90 days. 11.10% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.